Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)
John M.S. Bartlett(Edinburgh Cancer Research), Christopher Poole(Guy's Hospital), Janet Dunn(National Health Service), Daniel Rea(University Hospitals Birmingham NHS Foundation Trust), Jeremy Thomas(Western General Hospital), Alison F. Munro(Edinburgh Cancer Research), Elena Provenzano(University of Cambridge), Helena Earl(University of Cambridge), David Cameron(Corewell Health), Carlos Caldas(University of Cambridge), Louise Hiller(University of Warwick), Fiona Campbell(University of Birmingham), Sarah Jordan(Cancer Research UK Clinical Trials Unit), Christopher C. McConkey(University of Warwick), Paul D.P. Pharoah(Cedars-Sinai Medical Center), Chris Twelves(University of Leeds)
Cited by 127
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k